Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0TZEP)

Drug Name
Bamosiran Drug Info
Synonyms SYL040012
Indication
Disease Entry ICD 11 Status REF
Glaucoma/ocular hypertension 9C61 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM0TZEP

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ADRB2 messenger RNA (ADRB2 mRNA) TTG8ZWP ADRB2_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
ADRB2 messenger RNA (ADRB2 mRNA) DTT ADRB2 7.09 5.67 5.558 5.603
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Glaucoma/ocular hypertension
ICD Disease Classification 9C61
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
ADRB2 messenger RNA (ADRB2 mRNA) DTT ADRB2 1.10E-01 0.55 0.97
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02250612) SYL040012, Treatment for Open Angle Glaucoma (SYLTAG). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Sylentis.